ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Replimune Group, Inc. securities during the specified Class Period, alleging that the company made materially false and misleading statements regarding its business and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between November 22, 2024, and July 21, 2025 [1]. - The lawsuit claims that defendants overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate, leading to misleading statements about Replimune's business and operations [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by September 22, 2025, to represent other class members [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].